• Prestige Consumer Healthcare’s FY27 second-quarter diluted earnings fell 38% year over year to $0.53 per share.
• Quarterly revenue climbed 23% to $336.3 million, including a $65.1 million contribution from the Breathe Right portfolio and LaCorium acquisitions.
• First-half operating cash flow dropped 20% year over year to $108.65 million.
• Clear Eyes production variability at Pillar5 is expected to reduce product availability and revenue in the second half of FY27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050600PRIMZONEFULLFEED9871028) on November 05, 2026, and is solely responsible for the information contained therein.